{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"12/05/2022",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "23724914",
        "27401242",
        "25688157",
        "25351743",
        "24047073"
      ]
    },
    "description":"The ROS1 G2032R mutation is located in the protein's kinase domain and is associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (PMID: 25688157, 24047073, 23724914). In vitro studies demonstrated that G2032R confers resistance by interfering with crizotinib binding (PMID: 25351743). This mutation corresponds to the G1202R ALK kinase domain mutant (PMID: 23724914, 27401242).",
    "knownEffect":"Likely Gain-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"G2032R",
    "alterationType":null,
    "consequence":"missense_variant",
    "entrezGeneId":6098,
    "hgvs":null,
    "hugoSymbol":"ROS1",
    "id":null,
    "proteinEnd":2032,
    "proteinStart":2032,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The ROS1 G2032R mutation is likely oncogenic.",
  "vus":false
}